<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>DSpace Collection:</title>
    <link>http://repository.usmf.md:80/handle/20.500.12710/13577</link>
    <description />
    <pubDate>Fri, 19 Jun 2026 16:33:11 GMT</pubDate>
    <dc:date>2026-06-19T16:33:11Z</dc:date>
    <item>
      <title>The Moldovan Medical Journal. February 2017, Vol. 60, No 1</title>
      <link>http://repository.usmf.md:80/handle/20.500.12710/16255</link>
      <description>Title: The Moldovan Medical Journal. February 2017, Vol. 60, No 1
Abstract: The journal was founded in 1958 on the initiative of Nicolae Testemitsanu, an outstanding expert in orthopedics, social medicine, and public health.&#xD;
Now the publisher of the journal is the Scientific Medical Association of Moldova and the journal has become the scientific peer-reviewed periodical Edition&#xD;
designed for specialists in the areas of medicine, dentistry, pharmacy, social medicine, and public health. From its debut the journal has striven to support&#xD;
the interests of Moldovan medicine concerning the new concepts of its development.&#xD;
The aim of the Moldovan Medical Journal is to provide the international community with the results of scientific researches performed in the medical&#xD;
institutions of Moldova and inform Moldovan medical society about the advanced achievements of medicine abroad.&#xD;
The Editorial Board warmly welcomes both the readers of and the authors of the journal, all those who are enthusiastic about searching for new and more&#xD;
effective ways of solving numerous medical problems. We hope that those who want to make their contribution to the science of medicine will find our&#xD;
journal helpful and encouraging.
Description: Fondatori: Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie “Nicolae Testemiţanu”</description>
      <pubDate>Sun, 01 Jan 2017 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://repository.usmf.md:80/handle/20.500.12710/16255</guid>
      <dc:date>2017-01-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Infravesical urinary tract obstruction and transurethral endoscopic approach of treatment</title>
      <link>http://repository.usmf.md:80/handle/20.500.12710/2732</link>
      <description>Title: Infravesical urinary tract obstruction and transurethral endoscopic approach of treatment
Authors: Ghicavii, Vitalii
Abstract: Backqround: The results of scientifical progress in recent years have contributed to the development of transurethral endoscopic surgery, with the&#xD;
implementation of new methods, less invasive, for the treatment of the lower urinary tract diseases of different genesis. Laser surgery, transurethral&#xD;
electorezection, electrovaporization, bipolar surgery (plasmakinetic rezection and vaporization) and the combination of these methods have a number&#xD;
of avantages over traditional open interventions and contribute to a significant change in the treatment approach of most urological diseases, including&#xD;
those causing infravesical obstruction (IVO).&#xD;
Conclusions: The implementation of personalized medicine with correct selecting and pathogenetic motivation of the methods of treatement in&#xD;
management of the IVO have been made in several directions: prophylactics, diagnosis and treatment. Medical and social importance, variety of clinic&#xD;
manifestations and evolution, evident alternation of quality of life, high cost of diagnostic, conservative management and of surgical treatment determine&#xD;
the statuts of infravesical obstruction as a current problem from scientific and practical point of view and motivates the need of a deep study of disorders&#xD;
manifested through IVO, minimizing complications and the rate of their relapse.
Description: Department of Urology and Surgical Nephrology, Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova</description>
      <pubDate>Sun, 01 Jan 2017 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://repository.usmf.md:80/handle/20.500.12710/2732</guid>
      <dc:date>2017-01-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Surveillance of antimicrobials use in Emergency Medicine Institute</title>
      <link>http://repository.usmf.md:80/handle/20.500.12710/2731</link>
      <description>Title: Surveillance of antimicrobials use in Emergency Medicine Institute
Authors: Bernaz, Emilian P.; Ciobanu, Gheorghe Ch.; Tentiuc, Elizaveta V.; Borovic, Eduard I.; Vovc, Liviu A.
Abstract: Background: Antibiotics have had a profound impact on humanity’s health, by improving our ability to prevent, cure and reduce the transmission of&#xD;
many infectious diseases. It is widely known, that the unnecessary or inappropriate use of antibiotics, occurs up to 50% of prescriptions only in the United&#xD;
States and Canada. Fortunately all negative impact on the human health can be roughly imagined.&#xD;
Material and methods: For this study we used the data of a six-year (2009-2014) period in the Emergency Medicine Institute and their main subdivisions&#xD;
which show the consumption dynamics of antibacterials use in natural indexes.&#xD;
Results: The total annual medium consumption of antimicrobials was registered as the following: ICD 1796.98 DDD/1000, SSOTD 566.12 DDD/1000&#xD;
and EMI 584.05DDD/1000, with the parenteral to enteral forms share of respectively 94.67% to 5.33%, 85.62% to 14.38% and 83.52% to 16.48%. Five from&#xD;
nine main groups: beta-lactam antibacterials, penicilins, other beta-lactam, aminoglycoside, other antibacterials and quinolone antibacterials registered&#xD;
around 90% of all antibiotics consumption. Comparatively to Australian hospitals and hospitals other worldwide countries in EMI consumption per&#xD;
DDD/1000 was lower: by 3.39 and 2.22 times for tetracyclines, by 5.1 and 4.63 for beta-lactam and penicilins, as well as by 2.55 and 1.63 for macrolides&#xD;
and lincosamides.&#xD;
Conclusions: The obtained data about the dynamics of antibacterials consumption in EMI and their main departments, in comparison with hospitals&#xD;
from other worldwide countries, represents important arguments and reserves for improving quality treatment, planning, rational prescription and&#xD;
utilization of antibiotics in hospitals.
Description: Department of Medical Emergency, Nicolae Testemitsanu State University of Medicine and Pharmacy, Department of Quality of Medical Services Management, Emergency Medicine Institute, Medicines and Medical Devices Agency, Chisinau, the Republic of Moldova</description>
      <pubDate>Sun, 01 Jan 2017 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://repository.usmf.md:80/handle/20.500.12710/2731</guid>
      <dc:date>2017-01-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Experimental study of new 3-(2-R1 -6-R2 -4-oxyquinoline-3(4H)-yl)alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound)</title>
      <link>http://repository.usmf.md:80/handle/20.500.12710/2729</link>
      <description>Title: Experimental study of new 3-(2-R1 -6-R2 -4-oxyquinoline-3(4H)-yl)alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound)
Authors: Kramar, Hanna
Abstract: Background: Screening studies have revealed in new 3-(2-R1-6-R2-4-oxyquinoline-3(4H)-yl)alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66&#xD;
compound) expressive analgesic properties without any damaging effects on the stomach. Therefore, in-depth study of the pharmacological properties&#xD;
of PC-66 compound as a pain management agent is considered topical. Objective of the study – to evaluate a pain-killing effect of PC-66 compound&#xD;
compared to ketorolac and diclofenac sodium on various rat pain models.&#xD;
Material and methods: In experiments on 101 Wistar male rats (180-210 g) of somatic model (tail-flick) and neuropathic pain model (ligation of the&#xD;
sciatic nerve), and formalin test (5% formalin solution, 0.1 ml subplantarly) we investigated the antinociceptive activity of the PC-66 compound (1.0 mg/&#xD;
kg) versus ketorolac (2.4 mg/kg) and diclofenac (4.0 mg/kg) administered intraperitoneally.&#xD;
Results: In the tail-flick model, PC-66 compound presented significant growth of PT at Hour 1 and Hour 2 by 40.6% and 50.6%, respectively. The analgesia&#xD;
effect of the test compound was superior to the one of diclofenac sodium, but inferior to ketorolac at Hour 1 and Hour 2, yet surpassed it by duration&#xD;
of action. In the formalin test model, analgesic effect of compound PC-66 was the most evident in the first (central) phase, and slightly changed the&#xD;
latent period and duration of the second phase of the test, while diclofenac mostly influenced Phase II (inflammatory) of the formalin test. In the model&#xD;
of neuropathic pain, compound PC-66 also demonstrated pronounced pain-killing effect: PT of subject rat limb grew on average by 46.7% in 2 hours&#xD;
following intraperitoneal administration. For this activity, PC-66 was slightly inferior to ketorolac, which caused PT growth by 51.9%.&#xD;
Conclusions: new 3-(2-R1-6-R2-4-oxyquinoline-3(4H)-yl) alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound) presented distinct analgesic&#xD;
effect both in somatic and neuropathic pain models.
Description: Department of Pharmacology, N. I. Pirogov National Medical University of Vinnitsa, Ukraine</description>
      <pubDate>Sun, 01 Jan 2017 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://repository.usmf.md:80/handle/20.500.12710/2729</guid>
      <dc:date>2017-01-01T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

